This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): milnacipran, Dalcipran, Ixel, Toledomin, Impulsor
Description: Milnacipran is the first of a new class of agents known as norepinephrine serotonin reuptake inhibitors, or NSRIs. Milnacipran preferentially blocks the reuptake ofnorepinephrine over that of serotonin (5-HT). While milnacipran is similar to TCAs with regard to the relative ratio of norepinephrine and serotonin activity, milnacipran appears to lack the side effects associated with TCAs, as it does not interact with several classes of receptors that are responsible for many of the adverse effects of TCAs.
Cypress and Pierre Fabre
In August 2001, Cypress obtained an exclusive license for milnacipran from Pierre Fabre Medicament to develop and sell any products with the compound milnacipran as an active ingredient for any indication in the United States and Canada. The agreement was amended and restated in January 2004. Cypress paid Pierre Fabre a total of $2.5million, including upfront payments of $1.5million in connection with the execution of the original license agreement in 2001 and a $1.0 million milestone payment in September 2003, and issued Pierre Fabre 1,000,000 shares of common stock and warrants to purchase 300,000 shares of common stock in connection with an amendment to the agreement with Pierre Fabre. Cypress is obligated to pay Pierre Fabre 5% of any upfront and milestone payments received from Forest Laboratories as a sublicense fee. After a total of $7.5 million has been paid, any additional sublicense fees are credited against any subsequent milestone and...See full deal structure in Biomedtracker
Partners: Royalty Pharma AG Pierre Fabre Medicament S.A. Asahi Kasei Corporation
Pink Sheet Savella Clinical Development
Additional information available to subscribers only: